Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive Navigation
icon
News Archive Navigation Language
Showing 13 results
December 2021
September 2021
-
Pulse UpdateFDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
-
Pulse UpdateNovartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients
-
Pulse UpdateNovartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee